Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Novak, David J ^a,b   Chen, Long Qi ^a,c   Ghadirian, Parviz ^d   Hamel, Nancy ^a,e   Zhang, Phil ^f   Rossiny, Vanessa ^e   Cardinal, Guy ^g,h   Robidoux, André ⁱ   Tonin, Patricia N ^a,e   Rousseau, Francois ^g,h   Narod, Steven A ^f   Foulkes, William D ^a,b,e,g  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h Université Laval   (Canada)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANADA; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; BREAST TUMOR; ETHNOLOGY; FOUNDER EFFECT; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CANADA; FEMALE; FOUNDER EFFECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; PROTEIN-SERINE-THREONINE KINASES; VARIATION (GENETICS);

EID: 51649099539     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-239     Document Type: Article

References (39)

1. Parkin DM Bray F Ferlay J Pisani P Global cancer statistics, 2002 Ca-A Cancer Journal for Clinicians 2005, 55:74-108 15761078
2. Brody LC CHEKs and balances: Accounting for breast cancer Nature Genetics 2002, 31:3-4 10.1038/ng0502-3 11984555
3. Ford D Easton DF Stratton M Narod S Goldgar D Devilee P Bishop DT Weber B Lenoir G Chang-Claude J Sobol H Teare MD Struewing J Arason A Scherneck S Peto J Rebbeck TR Tonin P Neuhausen S Barkardottir R Eyfjord J Lynch H Ponder BA Gayther SA Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet 1998, 62:676-689 1376944 9497246 10.1086/301749
4. Chehab NH Malikzay A Appel M Halazonetis TD Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53 Genes & Development 2000, 14:278-288 316357 10673500
5. Lee JS Collins KM Brown AL Lee CH Chung JH hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response Nature 2000, 404:201-204 10.1038/35004614 10724175
6. Yang ST Kuo C Bisi JE Kim MK PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2 Nature Cell Biology 2002, 4:865-870 10.1038/ncb869 12402044
7. Meijers-Heijboer H van den Ouweland A Klijn J Wasielewski M de Snoo A Oldenburg R Hollestelle A Houben M Crepin E van Veghel-Plandsoen M Elstrodt F van Duijn C Bartels C Meijers C Schutte M McGuffog L Thompson D Easton DF Sodha N Seal S Barfoot R Mangion J Chang-Claude J Eccles D Eeles R Evans DG Houlston R Murday V Narod S Peretz T Peto J Phelan C Zhang HX Szabo C Devilee P Goldgar D Futreal PA Nathanson KL Weber BL Rahman N Stratton MR Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations Nature Genetics 2002, 31:55-59 10.1038/ng879 11967536
8. Vahteristo P Bartkova J Eerola H Syrjakoski K Ojala S Kilpivaara O Tamminen A Kononen J Aittomaki K Heikkila P Holli K Blomqvist C Bartek J Kallioniemi OP Nevanlinna H A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer American Journal of Human Genetics 2002, 71:432-438 379177 12094328 10.1086/341943
9. Easton D McGuffog L Thompson D Dunning A Tee L Baynes C Healey C Pharoah P Ponder B Seal S Barfoot R Sodha N Eeles R Stratton M Rahman N Peto J Spurdle AB Chen XQ Chenevix-Trench G Hopper JL Giles GG McCredie MRE Syrjakoski K Holli K Kallioniemi O Eerola H Vahteristo P Blomqvist C Nevanlinna H Kataja V Mannermaa A Dork T Bremer M Devilee P de Bock GH Krol-Warmerdam EMM Kroese-Jansema K Wijers-Koster P Cornelisse CJ Tollenaar RAEM Meijers-Heijboer H Berns E Nagel J Foekens J Klijn JGM Schutte M CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies American Journal of Human Genetics 2004, 74:1175-1182 1182081 15122511 10.1086/421251
10. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies Am J Hum Genet 2004, 74:1175-1182 1182081 15122511 10.1086/421251
11. Kleibl Z Novotny J Bezdickova D Malik R Kleiblova P Foretova L Petruzelka L Ilencikova D Cinek P Pohlreich P The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic Breast Cancer Research and Treatment 2005, 90:165-167 10.1007/s10549-004-4023-8 15803363
12. Wagenius M Borg A Johansson L Giwercman A Bratt O CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden Scandinavian Journal of Urology and Nephrology 2006, 40:23-25 10.1080/00365590500368518
13. Margolin S Eiberg H Lindblom A Bisgaard ML CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer Bmc Cancer 2007, 7 1994956 17705858
14. Shaag A Walsh T Renbaum P Kirchhoff T Nafa K Shiovitz S Mandell JB Welcsh P Lee MK Ellis N Offit K Levy-Lahad E King MC Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population Human Molecular Genetics 2005, 14:555-563 10.1093/hmg/ddi052 15649950
15. Dong XY Wang L Taniguchi K Wang XS Cunningham JM McDonnell SK Qian CP Marks AF Slager SL Peterson BJ Smith BI Cheville JC Blute ML Jacobsen SJ Schaid DJ Tindall DJ Thibodeau SN Liu WG Mutations in CHEK2 associated with prostate cancer risk American Journal of Human Genetics 2003, 72:270-280 379222 12533788 10.1086/346094
16. Cybulski C Huzarski T Gorski B Masojc B Mierzejewski M Debniak T Gliniewicz B Matyjasik J Zlowocka E Kurzawski G Sikorski A Posmyk M Szwiec M Czajka R Narod SA Lubinski J Novel founder CHEK2 mutation is associated with increased prostate cancer risk Cancer Research 2004, 64:2677-2679 10.1158/0008-5472.CAN-04-0341 15087378
17. Bogdanova N Enssen-Dubrowinskaja N Feshchenko S Lazjuk GI Rogov YI Dammann O Bremer M Karstens JH Sohn C Dork T Association of two mutations in the CHEK2 gene with breast cancer International Journal of Cancer 2005, 116:263-266 10.1002/ijc.21022 15810020
18. Walsh T Casadei S Coats KH Swisher E Stray SM Higgins J Roach KC Mandell J Lee MK Ciernikova S Foretova L Soucek P King MC Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer Jama-Journal of the American Medical Association 2006, 295:1379-1388 10.1001/jama.295.12.1379 16551709
19. Laberge AM Michaud J Richter A Lemyre E Lambert M Brais B Mitchell GA Population history and its impact on medical genetics in Quebec Clinical Genetics 2005, 68:287-301 10.1111/j.1399-0004.2005.00497.x 16143014
20. Scriver CR Human genetics: Lessons from Quebec populations Annual Review of Genomics and Human Genetics 2001, 2:69-101 10.1146/ annurev.genom.2.1.69 11701644
21. Tonin PN Mes-Masson AM Futreal PA Morgan K Mahon M Foulkes WD Cole DEC Provencher D Ghadirian P Narod SA Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families American Journal of Human Genetics 1998, 63:1341-1351 1377544 9792861 10.1086/302099
22. Oros KK Leblanc G Arcand SL Shen Z Perret C Mes-Masson AM Foulkes WD Ghadirian P Provencher D Tonin PN Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families Bmc Medical Genetics 2006, 7 1464093 16539696
23. Simard J Dumont M Moisan AM Gaborieau V Vezina H Durocher F Chiquette J Plante M Avard D Bessette P Brousseau C Dorval M Godard B Houde L Joly Y Lajoie MA Leblanc G Lepine J Lesperance B Malouin H Parboosingh J Pichette R Provencher L Rheaume J Sinnett D Samson C Simard JC Tranchant M Voyer P Easton D Tavtigian SV Knoppers BM Laframboise R Bridge P Goldgar D Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer Journal of Medical Genetics 2007, 44:107-121 10.1136/jmg.2006.044388 16905680
24. Foulkes WD Ghadirian P Akbari MR Hamel N Giroux S Sabbaghian N Darnel A Royer R Poll A Fafard E Robidoux A Martin G Bismar TA Tischkowitz M Rousseau F Narod SA Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women Breast Cancer Res 2007, 9:R83 2246183 18053174 10.1186/bcr1828
25. Giroux S Dube-Linteau A Cardinal G Labelle Y Laflamme N Giguere Y Rousseau F Assessment of the prevalence of the 985A > G MCAD mutation in the French-Canadian population using allele-specific PCR Clinical Genetics 2007, 71:569-575 10.1111/j.1399-0004.2007.00809.x 17539907
26. Houlston RS Peto J The search for low-penetrance cancer susceptibility alleles Oncogene 2004, 23:6471-6476 10.1038/sj.onc.1207951 15322517
27. Walsh T King MC Ten genes for inherited breast cancer Cancer Cell 2007, 11:103-105 10.1016/j.ccr.2007.01.010 17292821
28. Campeau PM Foulkes WD Tischkowitz MD Hereditary breast cancer: New genetic developments, new therapeutic avenues Hum Genet 2008, 124:31-42 10.1007/s00439-008-0529-1 18575892
29. Schutte M Seal S Barfoot R Meijers-Heijboer H Wasielewski M Evans DG Eccles D Meijers C Lohman F Klijn J van den Ouweland A Futreal PA Nathanson KL Weber BL Easton DF Stratton MR Rahman N Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility American Journal of Human Genetics 2003, 72:1023-1028 1180332 12610780 10.1086/373965
30. Bell DW Varley JM Szydlo TE Kang DH Wahrer DCR Shannon KE Lubratovich M Verselis SJ Isselbacher KJ Fraumeni JF Birch JM Li FP Garber JE Haber DA Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome Science 1999, 286:2528-2531 10.1126/science.286.5449.2528 10617473
31. Bell DW Kim SH Godwin AK Schiripo TA Harris PL Haserlat SM Wahrer DCR Haiman CA Daly MB Niendorf KB Smith MR Sgroi DC Garber JE Olopade OI Le Marchand L Henderson BE Altshuler D Haber DA Freedman ML Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts International Journal of Cancer 2007, 121:2661-2667 10.1002/ijc.23026
32. Zhang SY Phelan CM Zhang P Rousseau F Ghadirian P Robidoux A Foulkes W Hamel N McCready D Trudeau M Lynch H Horsman D De Matsuda MLL Aziz Z Gomes M Costa MM Liede A Poll A Sun P Narod SA Frequency of the CHEK2 1100delC mutation among women with breast cancer: An international study Cancer Research 2008, 68:2154-2157 10.1158/0008-5472.CAN-07-5187 18381420
33. Weischer M Bojesen SE Ellervik C Tybjaerg-Hansen A Nordestgaard BG CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: Meta-analyses of 26,000 patient cases and 27,000 controls J Clin Oncol 2008, 26:542-548 10.1200/JCO.2007.12.5922 18172190
34. Allinen M Huusko P Mantyniemi S Launonen V Winqvist R Mutation analysis of the CHK2 gene in families with hereditary breast cancer British Journal of Cancer 2001, 85:209-212 10.1054/bjoc.2001.1858 11461078
35. Sullivan A Yuille M Repellin C Reddy A Reelfs O Bell A Dunne B Gusterson BA Osin P Farrell PJ Yulug I Evans A Ozcelik T Gasco M Crook T Concomitant inactivation of p53 and Chk2 in breast cancer Oncogene 2002, 21:1316-1324 10.1038/sj.onc.1205207 11857075
36. Cybulski C Gorski B Huzarski T Masojc B Mierzejewski M Debniak T Teodorczyk U Byrski T Gronwald J Matyjasik J Zlowocka E Lenner M Grabowska E Nej K Castaneda J Medrek K Szymanska A Szymanska J Kurzawski G Suchy J Oszurek O Witek A Narod SA Lubinski J CHEK2 is a multiorgan cancer susceptibility gene American Journal of Human Genetics 2004, 75:1131-1135 1182149 15492928 10.1086/426403
37. Cybulski C Wokolorczyk D Huzarski T Byrski T Gronwald J Gorski B Debniak T Masojc B Jakubowska A van de Wetering T Narod SA Lubinski J A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland Breast Cancer Research and Treatment 2007, 102:119-122 10.1007/ s10549-006-9320-y 16897426
38. Kilpivaara O Alhopuro P Vahteristo P Aaltonen LA Nevanlinna H CHEK2 I157T associates with familial and sporadic colorectal cancer Journal of Medical Genetics 2006, 43 16816021
39. Zlowocka E Cybulski C Gorski B Debniak T Slojewski M Wokolorczyk D Serrano-Fernandez P Matyjasik J van de Wetering T Sikorski A Scott RJ Lubinski J Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer International Journal of Cancer 2008, 122:583-586 10.1002/ijc.23099 17918154